Secukinumab10 mg/kg IV→150 mg SC(N=161) | Secukinumab10 mg/kg IV→75 mg SC(N=147) | |
Radiographic non-progressors, n/M (%) | 100/128 (78.1) | 92/123 (74.8) |
Anti-TNF-naïve patients | 78/100 (78.0) | 73/94 (77.7) |
Anti-TNF-experienced patients | 22/28 (78.6) | 19/29 (65.5) |
IV, intravenous; M, number of patients who have a non-missing response status in the treatment group; n, number of patients who are non-progression responders (non-progression responders were patients with a change from baseline of ≤0.5 in van der Heijde modified Total Sharp Score during the considered period); SC, subcutaneous; TNF, tumour necrosis factor.